Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind,randomized,placebo-controlled study on 160 patients

Abstract

The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three centres, recruiting 160 outpatients with MS experiencing significant problems from at least one of the following: spasticity, spasms, bladder problems, tremor or pain. The interventions were oromucosal sprays of matched placebo, or whole plant CBME containing equal amounts of delta-9- tetrahydrocannabinol (THC) and cannabidiol (CBD) at a dose of 2.5- 120 mg of each daily, in divided doses. The primary outcome measure was a Visual Analogue Scale (VAS) score for each patient’s most troublesome symptom. Additional measures included VAS scores of other symptoms, and measures of disability, cognition, mood, sleep and fatigue. Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to 48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P- 0.001). There were no significant adverse effects on cognition or mood and intoxication was generally mild.

Keywords

cannabidiol cannabinoids delta-9-tetrahydrocannabinol multiple sclerosis patient selected outcome randomized controlled trial spasticity

Get full access to this article

View all access options for this article.

References

Consroe P , Musty R , Rein J , Consroe P , Musty R , Rein J et al. The perceived effects of smoked cannabis on patients with multiple sclerosis . Eur Neurol 1997; 38: 44-48 .

Killstein J , Hoogervorst EL , Reif M , Kalkers NF , Van Loenen AC , Staats PG et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS . Neurology 2002; 58: 1404-1407 .

Petro DJ , Ellenberger C. Treatment of human spasticity with delta-9-THC . J Clin Pharmacol 1981; 21: 413S-16S .

Ungerleider T , Andyrsiak T , Fairbanks L , Ellison GW , Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis . Adv Alcohol Subst Abuse 1987; 7: 39-50 .

Baker D , Pryce G , Croxford JL , Brown P , Pertwee RG , Huffman JW et al. Cannabinoids control spasticity and tremor in multiple sclerosis model . Nature 2000; 404: 84-87 .

Martyn CN , Illis LS , Thom J. Nabilone in the treatment of multiple sclerosis . Lancet 1995; 345: 579-579 .

Meinck HM , Schonle PW , Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis . J Neurol 1989; 236: 120-122 .

Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis . Ann Neurol 1983; 13: 669-671 .

Robson P.

Cannabis as a medicine: time for the phoenix to rise?

BMJ 1998; 316: 1034-1035 .

10.

Williamson EM , Evans FJ. Cannabinoids in clinical practice . Drugs 2000 60: 1303-1314 .

11.

Gaoni Y , Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish . J Am Chem Soc 1964; 86: 1646-1647 .

12.

McPartland J , Russo E.

Cannabis and cannabis extracts: greater than the sum of their parts?

J Cannabis Therap 2001; 1: 103-132 .

13.

Mechoulam R. Cannabinoid chemistry. In Mechoulam R ed. Marijuana-chemistry, pharmacology, metabolism and clinical effects. London: Academic Press , 1973: 1-99.

14.

Whittle BA , Guy GW , Robson P. Prospects for new cannabis-based prescription medicines . J Cannabis Therap 2001; 1: 183-205 .

15.

Robson PJ , Guy GW. Clinical studies of cannabis-based medicines. In Guy GW , Whittle BA , Robson PJ eds. The medicinal uses of cannabis and cannabinoids. London: Pharmaceutical Press , 2004: 229-269.

16.

Wade DT , Robson PJ , House H , Makela PM , Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms . Clin Rehab 2003; 17: 21-29 .

17.

Zajicek J , Fox P , Sanders H , Wright D , Vickery J , Nunn A , Thompson A on behalf of the UK MS research group . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial . Lancet 2003; 362: 1517-1526 .

18.

Campbell FA , Tramer MR , Carroll D , Reynolds DJ , Moore RA , McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review . BMJ 2001; 323: 13-16 .

19.

Patton GC , Coffey C , Carlin JB , Degenhardt L , Lynskey M , Hall W. Cannabis use and mental health in young people: cohort study . BMJ 2002; 325: 1195-1198 .

20.

Collin C , Wade DT , Davis S , Horne V. The Barthel ADL Index: a reliability study . Int Disabil Stud 1988; 10: 61-63 .

21.

Forlander DA , Bohannon RW. Rivermead Mobility Index: a brief review of research to date . Clin Rehab 1999; 13: 97-100 .

22.

Wade DT , Vergis E. The Short Orientation-Memory-Concentration test: a study of its reliability and validity . Clin Rehab 1999; 13: 164-170 .

23.

Vlaar AM , Wade DT. The Adult Memory & Information Processing Battery (AMIPB) test of information processing speed: a study of its reliability and feasibility in patients with multiple sclerosis . Clin Rehab 2003; 17: 386-393 .

24.

Goldberg DP , Hillier VF. A scaled version of the General Health Questionnaire . Psychol Med 1979; 9: 139-145 .

25.

Rossier P , Wade DT. The Guy’s Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity . Clin Rehab 2002; 16: 75-95 .

26.

Beck AT , Ward CH , Mendelson M , Mock JE , Erbaugh JK. An inventory for measuring depression . Arch Gen Psychiatry 1961; 4: 561-571 .

27.

Krupp LB , LaRocca NG , Muir-Nash J , Steinberg AF. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus . Arch Neurol 1989; 46: 1121-1123 .

28.

Gregson JM , Leathley M , Moore AP , Sharma AK , Smith TL , Watkins CL. Reliability of the Tone Assessment Scale and the Modified Ashworth scale as clinical tools for assessing post-stroke spasticity . Arch Phys Med Rehab 1999; 80: 1013-1016 .

29.

Alusi SH , Worthington J , Glickman S , Findley LJ , Bain PG. Evaluation of three different ways of assessing tremor in multiple sclerosis . J Neurol Neurosurg Psychiatry 2000; 68: 756-760 .

30.

Heller A , Wade DT , Wood VA , Sunderland A , Langton Hewer R , Ward E. Arm function after stroke: measurement and recovery over the first three months . J Neurol Neurosurg Psychiatry 1987; 50: 714-719 .

31.

Vahtera T , Haaranen M , Viramo-Koskela AL , Ruutiainen J. Pelvic floor rehabilitation is effective in multiple sclerosis . Clin Rehab 1997; 11: 211-221 .

32.

Lockwood K , Joyce B , Stolee P. Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients . J Clin Epidemiol 1997; 50: 581-588 .

33.

Donnelly C , Carswell A. Individualized outcome measures: a review of the literature . Can J Occup Ther 2002; 69: 84-94 .

34.

Farrar JT , Young JP Jr , LaMoreaux L , Werth JL , Poole RM. Clinical Importance of changes in chronic pain intensity measured on an 11-point numerical rating scale . Pain 2001; 94: 149-158 .